| CDE ID | CDE Description | | * 1063 | Site Participant ID (Go To: 422) |
| * 422 | EDRN Site ID (Go To: 423) |
| * 423 | EDRN Protocol ID (Go To: 1219) |
| * 1219 | Date of contact (MM/DD/YYYY): (Go To: 2733) |
| * 2733 | Proposed study group (Go To: 1292) |
| | | Permissible Values (value): | Set B Cases: Lung cancer (CT screening) (6) |
|
| 1292 | Height [in inches] (What is your total current height in inches?) (Go To: 1295) |
| 1295 | Weight [in pounds] (What is your current weight [in pounds]? (Go To: 1272) |
| 1272 | Living status: (Go To: 1218) |
| | | Permissible Values (value): | Alive with disease (1) |
|
| | | | Alive with no evidence of disease (NED) (2) |
|
| | |
| | |
| 1218 | Last date known alive (MM/DD/YYYY): (Go To: 1336) |
| 1336 | Date of death (MM/DD/YYYY): (Go To: 1332) |
| 1332 | Cause of death: (Go To: 1271) |
| 1271 | Comorbidities: (Go To: 1220) |
| | | Permissible Values (value): | Myocardial infarction (1) |
|
| | | | Congestive heart failure (2) |
|
| | | | Peripheral vascular disease (3) |
|
| | | | Cerebrovascular disease (4) |
|
| | |
| | | | Chronic pulmonary disease (6) |
|
| | | | Connective tissue disease (7) |
|
| | |
| | |
| | |
| | |
| | | | Moderate or severe renal disease (12) |
|
| | | | Diabetes with end organ damage (13) |
|
| | | | Moderate or severe liver disease (14) |
|
| | | | Metastatic solid tumor (15) |
|
| | |
| 1220 | Disease status: (Go To: 1276) |
| | | Permissible Values (value): | Relapsed (1) |
|
| | |
| | |
| | |
| | |
| | |
| | | | No evidence of disease (7) |
|
| | |
| 1276 | Disease free survival (DFS)? (Go To: 1280) |
| | | Permissible Values (value): | No (0) |
|
| | |
| 1280 | Overall survival (OS) in days: (Go To: 1221) |
| 1221 | Recurrence date (MM/YYYY): (Go To: 1222) |
| 1222 | Recurrence site: (Go To: 1277) |
| | | Permissible Values (value): | Bladder (1) |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | | | Head & neck (mouth, nose, and throat) (8) |
|
| | |
| | |
| | |
| | |
| | | | Lymphoma, including Hodgkins (13) |
|
| | |
| | |
| | |
| | |
| | | | Skin (melanoma, no basal or squamous) (18) |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 1277 | Time to local recurrence (TTLR): (Go To: 1223) |
| 1223 | Progression date (MM/YYYY): (Go To: 1224) |
| 1224 | Progression site: (Go To: 1275) |
| | | Permissible Values (value): | Bladder (1) |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | | | Head & neck (mouth, nose, and throat) (8) |
|
| | |
| | |
| | |
| | |
| | | | Lymphoma, including Hodgkins (13) |
|
| | |
| | |
| | |
| | |
| | | | Skin (melanoma, no basal or squamous) (18) |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 1275 | Time to progression in days (TTP): (Go To: 1097) |
| 1097 | Comments (do not include any participant identifiers) (Go To: End of Form) |